Delay in MAA for Asit Biotechs BTT009 Belgian Asit Biotech S.A. (formerly Biotech Tools) has announced that its grass pollen allergic rhinitis immunotherapy gp-ASIT+ did reach the primary efficacy endpoint in a Phase III trial but needs … more ➔
J&J completes acquisition of ActelionAfter todays completion of the acquisition of Actelion Ltd by J&J for US$30bn in cash, equivalent to US$280 per share, through the US companys Swiss subsidiary, Janssen Holding GmbH, Actelion … more ➔
Boehringer Ingelheims Humira biosimilar...Boehringer Ingelheim has presented detailed pivotal double-blinded Phase III data, which prove comparability of its biosimilar candidate BI695501 to Humira in patients with moderate to severe Rheumatoid … more ➔
Medicxi launches €267m fundNovartis and Alphabet/Google asset Verily Life Sciences LLC has co-invested into the late stage fund designed to finance programmes with up to €25m post clinical proof of concept. more ➔
Germany is blocking EU Unitary Patent Cour...Germanys Constitutional Court has stopped the government from ratifying the EUs Unitary Patent Package. At the time of the announcement, The German Bundestag and Council of Federal states had already … more ➔
Abivax Ebola antiviral gets financing French virology company Abivac will receive €390,000 for the development of a polyclonal antibody cocktail to fight Ebola. more ➔
Centogene raises a €25m in Series A fina...Orphan diseases diagnostics specialist Centogene AG said it will use the funds for biomarker and CDx development based on its proprietary CentoMD mutation database. more ➔
Bonesupport is planning €60m IPO Swedish orthobiologics company Bonesupport Holding AB announced on Sunday it will go public at Nasdaq Stockholm. more ➔
Targovax raises €21m in private placemen...Norwegian cancer med developer Targovax ASA has doubled its cash and cash equivalents as of 31 December 2016 by raising NOK200m (€21m) in a private placement of new shares. more ➔
Grünenthal in US$300m deal with AstraZene...German Grünenthal Group has entered into an agreement to acquire the global rights to AstraZenecas migraine treatment Zolmitriptan. more ➔